LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

AZN

185.95

+2.31%↑

Strona główna・Stock List・Merck & Co Inc.

Merck & Co Inc.

Closed

SectorHealthcare

120.93 0.57

Buy Sell

Overview

Share price change

24h

Current

Min

120.76

Max

121.63

Key metrics
By Trading Economics
Income	-7.2B -4.2B
Sales	-114M 16B
P/E Sector Avg	32.442 49.888
EPS	-1.28
Dividend yield	2.76
Profit margin	-26.053
Employees	73,000
EBITDA	-6.2B -1.9B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+13.01% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	2.76% 2.38%
Next Earnings	4 sie 2026
Next Dividend date	8 lip 2026
Next Ex Dividend date	15 cze 2026

Market Stats
By TradingEconomics
Market Cap	12B 284B
Previous open	120.36
Previous close	120.93

News Sentiment

By Acuity

32%

68%

72 / 344 Ranking in Healthcare

Merck & Co Inc. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 kwi 2026, 14:20 UTC

Earnings

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30 kwi 2026, 10:45 UTC

Earnings

Merck 1Q Sales Rise on Continued Keytruda Growth

5 maj 2026, 18:12 UTC

Earnings

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 maj 2026, 13:54 UTC

Earnings

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 maj 2026, 12:48 UTC

Acquisitions, Mergers, Takeovers

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5 maj 2026, 12:48 UTC

Acquisitions, Mergers, Takeovers

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5 maj 2026, 12:47 UTC

Acquisitions, Mergers, Takeovers

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5 maj 2026, 12:45 UTC

Acquisitions, Mergers, Takeovers

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1 maj 2026, 18:35 UTC

Earnings

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 maj 2026, 14:53 UTC

Earnings

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30 kwi 2026, 13:27 UTC

Earnings

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30 kwi 2026, 10:47 UTC

Earnings

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30 kwi 2026, 10:30 UTC

Earnings

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck 1Q Animal Health Sales Up 13% >MRK

30 kwi 2026, 10:30 UTC

Earnings

Merck 1Q Sales $16.29B >MRK

Peer Comparison

Price change

Merck & Co Inc. Forecast

Price Target

By TipRanks

13.01% upside

12 Months Forecast

Average 136.5 USD 13.01%

High 179 USD

Low 112 USD

Based on 19 Wall Street analysts offering 12 month price targets forMerck & Co Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Merck & Co Inc. - Dist in the past 3 months.

Sentiment

By Acuity

72 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.